TIME TO DISCONTINUATION AND EFFECTIVENESS OF BARICITINIB IN RHEUMATOID ARTHRITIS: 12-MONTH EUROPEAN DATA FROM A MULTINATIONAL, PROSPECTIVE, OBSERVATIONAL STUDY

被引：0
|
作者：
Alten, Rieke [1 ]
Burmester, Gerd R. [2 ]
Matucci-Cerinic, Marco [3 ,4 ]
Ostor, Andrew [5 ]
Zaremba-Pechmann, Liliana [6 ]
Treuer, Tamas [7 ]
Ng, Khai Jing [7 ]
Gerwien, Jens [7 ]
Gibson, Kathryn A. [7 ]
Fautrel, Bruno [8 ,9 ]
Pile, Kevin [10 ]
机构：
[1] Univ Med Berlin, Dept Internal Med & Rheumatol, Schlossprk Klin, Berlin, Germany
[2] Charite Univ Med Berlin, Dept Rheumatol & Clin Immunol, Berlin, Germany
[3] Univ Florence, Div Rheumatol, Florence, Italy
[4] IRCCS San Raffaele Hosp, Unit Immunol Rheumatol Allergy & Rare Dis UnIRAR, Milan, Italy
[5] Monash Univ, Cabrini Hosp, Melbourne, Australia
[6] HaaPACS GmbH, Schriesheim, Germany
[7] Eli Lilly & Co, Indianapolis, IN 46285 USA
[8] Sorbonne Univ, Assistance Publ Hop Paris, Pitie Salpetriere Hosp, Dept Rheumatol, Paris, France
[9] Pierre Louis Inst Epidemiol & Publ Hlth, PEPITES team, Paris, France
[10] Western Sydney Univ, Sydney, Australia
来源：
INTERNAL MEDICINE JOURNAL | 2023年 / 53卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
ARA-P67
引用
收藏
页码：36 / 37
页数：2
相关论文
共 50 条
  • [21] Effects of switching weekly alendronate or risedronate to monthly minodronate in patients with rheumatoid arthritis: a 12-month prospective study
    K. Ebina
    T. Noguchi
    M. Hirao
    J. Hashimoto
    S. Kaneshiro
    M. Yukioka
    H. Yoshikawa
    Osteoporosis International, 2016, 27 : 351 - 359
  • [22] A biopsychosocial model of pain and depression in rheumatoid arthritis: a 12-month longitudinal study
    Covic, T
    Adamson, B
    Spencer, D
    Howe, G
    RHEUMATOLOGY, 2003, 42 (11) : 1287 - 1294
  • [23] Prognosis of the infected diabetic foot ulcer: a 12-month prospective observational study
    Ndosi, M.
    Wright-Hughes, A.
    Brown, S.
    Backhouse, M.
    Lipsky, B. A.
    Bhogal, M.
    Reynolds, C.
    Vowden, P.
    Jude, E. B.
    Nixon, J.
    Nelson, E. A.
    DIABETIC MEDICINE, 2018, 35 (01) : 78 - 88
  • [24] Erenumab Discontinuation After 12-Month Treatment A Multicentric, Observational Real-Life Study
    di Cola, Francesca Schiano
    Caratozzolo, Salvatore
    Venturelli, Elisabetta
    Balducci, Ubaldo
    Sidoti, Vincenzo
    Pari, Elisa
    Costanzi, Chiara
    di Summa, Alfonsina
    Sixt, Gabriele Johanna
    D'Adda, Elisabetta
    Liberini, Paolo
    Rao, Renata
    Padovani, Alessandro
    NEUROLOGY-CLINICAL PRACTICE, 2021, 11 (06) : E834 - E839
  • [25] The impact of C-reactive protein levels on the effectiveness of upadacitinib in patients with rheumatoid arthritis: a 12-month prospective, non-interventional German study
    Witte, T.
    Kiltz, U.
    Haas, F.
    Riechers, E.
    Prothmann, U.
    Adolf, D.
    Holland, C.
    Rossler, A.
    Soppa, U.
    Fritz, B.
    Goetz, K.
    Kruger, K.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2024, 42 (03) : 726 - 735
  • [26] Nintedanib for progressive pulmonary fibrosis: 12-month outcome data from a multicentre observational study
    Raman, Lavanya
    Stewart, Iain
    Barratt, Shaney
    Chua, Felix
    Chaudhuri, Nazia
    Crawshaw, Anjali
    Gibbons, Michael
    Hogben, Charlotte
    Hoyles, Rachel
    Kouranos, Vasilis
    Martinovic, Jennifer
    Mulholland, Sarah
    Myall, Kate
    Naqvi, Marium
    Renzoni, Elisabetta A.
    Saunders, Peter
    Steward, Matthew
    Suresh, Dharmic
    Thillai, Muhunthan
    Wells, Athol U.
    West, Alex
    Mitchell, Jane A.
    George, Peter M.
    IRISH JOURNAL OF MEDICAL SCIENCE, 2022, 191 : S139 - S139
  • [27] Medication discontinuation with depot and oral antipsychotics in outpatients with schizophrenia: comparison of matched cohorts from a 12-month observational study
    Brnabic, A. J. M.
    Kelin, K.
    Ascher-Svanum, H.
    Montgomery, W.
    Kadziola, Z.
    Karagianis, J.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2011, 65 (09) : 945 - 953
  • [28] The RA-BE-REAL Multinational, Prospective, Observational Study in Patients with Rheumatoid Arthritis Receiving Baricitinib, Targeted Synthetic, or Biologic Disease-Modifying Therapies: a 6-Month Interim Analysis
    Rieke Alten
    Gerd R. Burmester
    Marco Matucci-Cerinic
    Jean-Hugues Salmon
    Pedro Lopez-Romero
    Walid Fakhouri
    Inmaculada de la Torre
    Liliana Zaremba-Pechmann
    Thorsten Holzkämper
    Bruno Fautrel
    Rheumatology and Therapy, 2023, 10 : 73 - 93
  • [29] The RA-BE-REAL Multinational, Prospective, Observational Study in Patients with Rheumatoid Arthritis Receiving Baricitinib, Targeted Synthetic, or Biologic Disease-Modifying Therapies: a 6-Month Interim Analysis
    Alten, Rieke
    Burmester, Gerd R.
    Matucci-Cerinic, Marco
    Salmon, Jean-Hugues
    Lopez-Romero, Pedro
    Fakhouri, Walid
    de la Torre, Inmaculada
    Zaremba-Pechmann, Liliana
    Holzkaemper, Thorsten
    Fautrel, Bruno
    RHEUMATOLOGY AND THERAPY, 2023, 10 (01) : 73 - 93
  • [30] Survival of bDMARDs in bionaive patients with rheumatoid arthritis: data from a retrospective 12-month follow-up
    Aronova, E. S.
    Lukina, G., V
    Glukhova, S., I
    Gridneva, G., I
    Kudryavtseva, A., V
    TERAPEVTICHESKII ARKHIV, 2020, 92 (05): : 39 - +
12345